5 news items
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
MBRX
13 May 24
Recruited
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
MBRX
9 May 24
complete response. Recruitment in MB-106 has ended for 2nd line subjects while recruitment for 1st line and 3rd line subjects continue. Annamycin
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
MBRX
7 May 24
of January 2024, the Company completed recruiting the desired number
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
MBRX
18 Apr 24
is developing. One subject has surpassed the one-year mark with a durable complete response. Recruitment in MB-106 has ended
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
MBRX
25 Mar 24
of January 2024, the Company completed recruiting the desired number of 2nd line
- Prev
- 1
- Next